---
schema_version: "secwatch.filing_event.v1"
accession: "0001070081-23-000036"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T19:42:20.907127+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics reports positive interim Phase 2 data for PTC518 in Huntington's disease

## Summary
- Interim data from PIVOT-HD Phase 2 study shows dose-dependent lowering of HTT protein in blood, with mean 30% reduction at 10mg dose.
- PTC518 treatment well tolerated; no treatment-related serious adverse events or dose-limiting toxicities reported.
- No CSF NfL treatment-related spikes; trend towards lowering of CSF NfL levels after 12 weeks.
- Conference call held June 21, 2023 at 8:00 AM EDT to discuss data; slides furnished as Exhibit 99.2.

## SEC filing metadata
- accession: 0001070081-23-000036
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000036/0001070081-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000107008123000036/tmb-20230621x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001070081-23-000036
- JSON: https://secwatch.observer/filing/0001070081-23-000036.json
- Plain text: https://secwatch.observer/filing/0001070081-23-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.